Increased circulating visfatin is associated with progression of kidney disease in non-diabetic hypertensive patients

Chien Yi Hsu, Po Hsun Huang, Tz Heng Chen, Chia Hung Chiang, Hsin Bang Leu, Chin Chou Huang, Jaw Wen Chen, Shing Jong Lin

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

BACKGROUD: Declining renal function is an independent risk factor for all-cause mortality in cardiovascular disease. Visfatin has been described as a marker of inflammation and endothelial dysfunction, but whether circulating visfatin levels are predictive to a subsequent decline in renal function remains unclear. METHODS: In total, 200 nondiabetic, non-proteinuric hypertensive outpatients with initial serum creatinine (Scr) ≤1.5 mg/dl were enrolled. Plasma visfatin concentration and endothelial function estimated by brachial artery flow-mediated dilatation (FMD) were determined in the study subjects. The primary endpoints were the occurrence of renal events including doubling of Scr, 25% loss of glomerular filtration rate (GFR) from baseline values, and the occurrence of end-stage renal disease during follow-up. RESULTS: The mean annual rate of GFR decline (ΔGFR/y) was -1.26 ± 2.76 ml/ min/1.73 m2 per year during follow-up (8.6 ± 2.5 years). At baseline, plasma visfatin was negatively correlated with estimated GFR. In longitudinal analysis, the ΔGFR/y was correlated with visfatin, baseline GFR, FMD, systolic blood pressure, and fasting blood glucose (FBG). Multivariate analysis indicated that increased visfatin (r = -0.331, P <0.001), baseline GFR (r = -0.234, P = 0.001), FMD (r = 0.163, P = 0.015), and FBG (r = -0.160, P = 0.015) are independent predictors of ΔEGFR/y. Cox regression model analysis showed that visfatin (hazard ratio (HR), 1.09; 95% confidence interval (CI), 1.05-1.13, P <0.001), FBG (HR, 1.01; 95% CI, 1.00-1.02, P = 0.020), and FMD (HR, 0.87; 95% CI, 0.76-1.00, P = 0.049) were independently associated with the risk of developing future renal events. CONCLUSIONS: Increased circulating visfatin are associated with subsequent decline in renal function in nondiabetic hypertensive patients.

Original languageEnglish
Pages (from-to)528-536
Number of pages9
JournalAmerican Journal of Hypertension
Volume29
Issue number4
DOIs
Publication statusPublished - Jan 1 2016
Externally publishedYes

Fingerprint

Nicotinamide Phosphoribosyltransferase
Kidney Diseases
Glomerular Filtration Rate
Dilatation
Kidney
Blood Glucose
Fasting
Confidence Intervals
Creatinine
Blood Pressure
Brachial Artery
Serum
Proportional Hazards Models
Chronic Kidney Failure
Outpatients
Cardiovascular Diseases
Multivariate Analysis
Regression Analysis
Inflammation

Keywords

  • Adipokine
  • Blood pressure
  • Chronic kidney disease
  • Endothelial dysfunction
  • Hypertension
  • Visfatin

ASJC Scopus subject areas

  • Internal Medicine

Cite this

Increased circulating visfatin is associated with progression of kidney disease in non-diabetic hypertensive patients. / Hsu, Chien Yi; Huang, Po Hsun; Chen, Tz Heng; Chiang, Chia Hung; Leu, Hsin Bang; Huang, Chin Chou; Chen, Jaw Wen; Lin, Shing Jong.

In: American Journal of Hypertension, Vol. 29, No. 4, 01.01.2016, p. 528-536.

Research output: Contribution to journalArticle

Hsu, Chien Yi ; Huang, Po Hsun ; Chen, Tz Heng ; Chiang, Chia Hung ; Leu, Hsin Bang ; Huang, Chin Chou ; Chen, Jaw Wen ; Lin, Shing Jong. / Increased circulating visfatin is associated with progression of kidney disease in non-diabetic hypertensive patients. In: American Journal of Hypertension. 2016 ; Vol. 29, No. 4. pp. 528-536.
@article{5ebb8ae660af4b6d8c44509267b618b0,
title = "Increased circulating visfatin is associated with progression of kidney disease in non-diabetic hypertensive patients",
abstract = "BACKGROUD: Declining renal function is an independent risk factor for all-cause mortality in cardiovascular disease. Visfatin has been described as a marker of inflammation and endothelial dysfunction, but whether circulating visfatin levels are predictive to a subsequent decline in renal function remains unclear. METHODS: In total, 200 nondiabetic, non-proteinuric hypertensive outpatients with initial serum creatinine (Scr) ≤1.5 mg/dl were enrolled. Plasma visfatin concentration and endothelial function estimated by brachial artery flow-mediated dilatation (FMD) were determined in the study subjects. The primary endpoints were the occurrence of renal events including doubling of Scr, 25{\%} loss of glomerular filtration rate (GFR) from baseline values, and the occurrence of end-stage renal disease during follow-up. RESULTS: The mean annual rate of GFR decline (ΔGFR/y) was -1.26 ± 2.76 ml/ min/1.73 m2 per year during follow-up (8.6 ± 2.5 years). At baseline, plasma visfatin was negatively correlated with estimated GFR. In longitudinal analysis, the ΔGFR/y was correlated with visfatin, baseline GFR, FMD, systolic blood pressure, and fasting blood glucose (FBG). Multivariate analysis indicated that increased visfatin (r = -0.331, P <0.001), baseline GFR (r = -0.234, P = 0.001), FMD (r = 0.163, P = 0.015), and FBG (r = -0.160, P = 0.015) are independent predictors of ΔEGFR/y. Cox regression model analysis showed that visfatin (hazard ratio (HR), 1.09; 95{\%} confidence interval (CI), 1.05-1.13, P <0.001), FBG (HR, 1.01; 95{\%} CI, 1.00-1.02, P = 0.020), and FMD (HR, 0.87; 95{\%} CI, 0.76-1.00, P = 0.049) were independently associated with the risk of developing future renal events. CONCLUSIONS: Increased circulating visfatin are associated with subsequent decline in renal function in nondiabetic hypertensive patients.",
keywords = "Adipokine, Blood pressure, Chronic kidney disease, Endothelial dysfunction, Hypertension, Visfatin",
author = "Hsu, {Chien Yi} and Huang, {Po Hsun} and Chen, {Tz Heng} and Chiang, {Chia Hung} and Leu, {Hsin Bang} and Huang, {Chin Chou} and Chen, {Jaw Wen} and Lin, {Shing Jong}",
year = "2016",
month = "1",
day = "1",
doi = "10.1093/ajh/hpv132",
language = "English",
volume = "29",
pages = "528--536",
journal = "American Journal of Hypertension",
issn = "0895-7061",
publisher = "Oxford University Press",
number = "4",

}

TY - JOUR

T1 - Increased circulating visfatin is associated with progression of kidney disease in non-diabetic hypertensive patients

AU - Hsu, Chien Yi

AU - Huang, Po Hsun

AU - Chen, Tz Heng

AU - Chiang, Chia Hung

AU - Leu, Hsin Bang

AU - Huang, Chin Chou

AU - Chen, Jaw Wen

AU - Lin, Shing Jong

PY - 2016/1/1

Y1 - 2016/1/1

N2 - BACKGROUD: Declining renal function is an independent risk factor for all-cause mortality in cardiovascular disease. Visfatin has been described as a marker of inflammation and endothelial dysfunction, but whether circulating visfatin levels are predictive to a subsequent decline in renal function remains unclear. METHODS: In total, 200 nondiabetic, non-proteinuric hypertensive outpatients with initial serum creatinine (Scr) ≤1.5 mg/dl were enrolled. Plasma visfatin concentration and endothelial function estimated by brachial artery flow-mediated dilatation (FMD) were determined in the study subjects. The primary endpoints were the occurrence of renal events including doubling of Scr, 25% loss of glomerular filtration rate (GFR) from baseline values, and the occurrence of end-stage renal disease during follow-up. RESULTS: The mean annual rate of GFR decline (ΔGFR/y) was -1.26 ± 2.76 ml/ min/1.73 m2 per year during follow-up (8.6 ± 2.5 years). At baseline, plasma visfatin was negatively correlated with estimated GFR. In longitudinal analysis, the ΔGFR/y was correlated with visfatin, baseline GFR, FMD, systolic blood pressure, and fasting blood glucose (FBG). Multivariate analysis indicated that increased visfatin (r = -0.331, P <0.001), baseline GFR (r = -0.234, P = 0.001), FMD (r = 0.163, P = 0.015), and FBG (r = -0.160, P = 0.015) are independent predictors of ΔEGFR/y. Cox regression model analysis showed that visfatin (hazard ratio (HR), 1.09; 95% confidence interval (CI), 1.05-1.13, P <0.001), FBG (HR, 1.01; 95% CI, 1.00-1.02, P = 0.020), and FMD (HR, 0.87; 95% CI, 0.76-1.00, P = 0.049) were independently associated with the risk of developing future renal events. CONCLUSIONS: Increased circulating visfatin are associated with subsequent decline in renal function in nondiabetic hypertensive patients.

AB - BACKGROUD: Declining renal function is an independent risk factor for all-cause mortality in cardiovascular disease. Visfatin has been described as a marker of inflammation and endothelial dysfunction, but whether circulating visfatin levels are predictive to a subsequent decline in renal function remains unclear. METHODS: In total, 200 nondiabetic, non-proteinuric hypertensive outpatients with initial serum creatinine (Scr) ≤1.5 mg/dl were enrolled. Plasma visfatin concentration and endothelial function estimated by brachial artery flow-mediated dilatation (FMD) were determined in the study subjects. The primary endpoints were the occurrence of renal events including doubling of Scr, 25% loss of glomerular filtration rate (GFR) from baseline values, and the occurrence of end-stage renal disease during follow-up. RESULTS: The mean annual rate of GFR decline (ΔGFR/y) was -1.26 ± 2.76 ml/ min/1.73 m2 per year during follow-up (8.6 ± 2.5 years). At baseline, plasma visfatin was negatively correlated with estimated GFR. In longitudinal analysis, the ΔGFR/y was correlated with visfatin, baseline GFR, FMD, systolic blood pressure, and fasting blood glucose (FBG). Multivariate analysis indicated that increased visfatin (r = -0.331, P <0.001), baseline GFR (r = -0.234, P = 0.001), FMD (r = 0.163, P = 0.015), and FBG (r = -0.160, P = 0.015) are independent predictors of ΔEGFR/y. Cox regression model analysis showed that visfatin (hazard ratio (HR), 1.09; 95% confidence interval (CI), 1.05-1.13, P <0.001), FBG (HR, 1.01; 95% CI, 1.00-1.02, P = 0.020), and FMD (HR, 0.87; 95% CI, 0.76-1.00, P = 0.049) were independently associated with the risk of developing future renal events. CONCLUSIONS: Increased circulating visfatin are associated with subsequent decline in renal function in nondiabetic hypertensive patients.

KW - Adipokine

KW - Blood pressure

KW - Chronic kidney disease

KW - Endothelial dysfunction

KW - Hypertension

KW - Visfatin

UR - http://www.scopus.com/inward/record.url?scp=84962535681&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84962535681&partnerID=8YFLogxK

U2 - 10.1093/ajh/hpv132

DO - 10.1093/ajh/hpv132

M3 - Article

VL - 29

SP - 528

EP - 536

JO - American Journal of Hypertension

JF - American Journal of Hypertension

SN - 0895-7061

IS - 4

ER -